Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022;29:213–9.

Article  PubMed  Google Scholar 

Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy. J Am Coll Cardiol. 2016;68:1323–41.

Article  PubMed  Google Scholar 

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2872–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.

Article  CAS  PubMed  Google Scholar 

Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: A practical approach. JACC Cardiovasc Imaging. 2020;13:1368–83.

Article  PubMed  Google Scholar 

Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–60.

Article  PubMed  Google Scholar 

Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci. 2012;109:9629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanguinetti C, Minniti M, Susini V, et al. The journey of human transthyretin: synthesis, structure stability, and catabolism. Biomedicines. 2022;10:1906.

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–123.

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27:659–73.

Article  PubMed  Google Scholar 

Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: Recent advances and focus on the future. J Nucl Med. 2023;64:20S-28S.

Article  CAS  PubMed  Google Scholar 

Guy CD, Jones CK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: Specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol. 2001;24:181–5.

Article  CAS  PubMed  Google Scholar 

Dasari S, Theis JD, Vrana JA, et al. Amyloid typing by mass spectrometry in clinical practice: A comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95:1852–64.

Article  CAS  PubMed  Google Scholar 

Linke RP. On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem. 2012;47:61–132.

Article  PubMed  Google Scholar 

Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–93.

Article  PubMed  Google Scholar 

Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5:897–907.

Article  PubMed  PubMed Central  Google Scholar 

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.

Article  CAS  PubMed  Google Scholar 

Dorbala S, Park MA, Cuddy S, et al. Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT. J Nucl Med. 2021;62:716–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clerc OF, Cuddy SAM, Robertson M, et al. Cardiac amyloid quantification using (124)I-evuzamitide ((124)I-P5+14) versus (18)F-florbetapir: A pilot PET/CT study. JACC Cardiovasc Imaging. 2023;16:1419–32.

Article  PubMed  PubMed Central  Google Scholar 

Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. (99m)Tc bone-avid tracer cardiac scintigraphy: Role in noninvasive diagnosis of transthyretin cardiac amyloidosis. Radiology. 2023;306:e221082.

Article  PubMed  Google Scholar 

Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26:158–73.

Article  PubMed  Google Scholar 

Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23:1187–226.

Article  PubMed  Google Scholar 

Kim YJ, Ha S, Kim YI. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J Nucl Cardiol. 2020;27:123–32.

Article  PubMed  Google Scholar 

Wu Z, Yu C. Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: A meta-analysis. BMC Cardiovasc Disord. 2021;21:482.

Article  PubMed  PubMed Central  Google Scholar 

Uzuegbunam BC, Librizzi D, Hooshyar Yousefi B. PET radiopharmaceuticals for Alzheimer’s disease and Parkinson’s disease diagnosis, the current and future landscape. Molecules. 2020;25:977.

Martin EB, Williams A, Heidel E, Macy S, Kennel SJ, Wall JS. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. Biochem Biophys Res Commun. 2013;436:85–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wall JS, Martin EB, Richey T, et al. Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis. Molecules. 2015;20:7657–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abulizi M, Sifaoui I, Wuliya-Gariepy M, et al. (18)F-sodium fluoride PET/MRI myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2021;28:1586–95.

Article  PubMed  Google Scholar 

Andrews JPM, Trivieri MG, Everett R, et al. 18F-fluoride PET/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls. J Nucl Cardiol. 2022;29:741–9.

Article  PubMed  Google Scholar 

Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. (18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018;25:1559–67.

Article  PubMed  Google Scholar 

Trivieri MG, Dweck MR, Abgral R, et al. (18)F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol. 2016;68:2712–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–20.

Article  CAS  PubMed  Google Scholar 

Lee SP, Lee ES, Choi H, et al. (11)C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8:50–9.

Article  PubMed  Google Scholar 

Pilebro B, Arvidsson S, Lindqvist P, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2018;25:240–8.

Article  PubMed  Google Scholar 

Takasone K, Katoh N, Takahashi Y, et al. Non-invasive detection and differentiation of cardiac amyloidosis using (99m)Tc-pyrophosphate scintigraphy and (11)C-Pittsburgh compound B PET imaging. Amyloid. 2020;27:266–74.

Article  CAS